Results 21 to 30 of about 278,540 (307)

Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco [PDF]

, 2014
The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most ...
EMEA, Montefiori D.C., Pabst M., Pegu A., WHO   +4 more
core   +1 more source

An investigation of the breadth of neutralising antibody response in cats naturally infected with feline immunodeficiency virus [PDF]

, 2015
Neutralising antibodies (NAbs) are believed to comprise an essential component of the protective immune response induced by vaccines against FIV and HIV infections.
Beczkowski, Pawel, Hosie, Margaret J., Litster, Annette, Logan, Nicola, McMonagle, Elizabeth, Willett, Brian J.   +5 more
core   +5 more sources

Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding

Nature Communications, 2017
Eliciting broadly neutralizing antibodies (bnAbs) is a primary HIV vaccine goal, but available immunogens expose epitopes for development of non-nAbs.
Daniel W. Kulp, Jon M. Steichen, Matthias Pauthner, Xiaozhen Hu, Torben Schiffner, Alessia Liguori, Christopher A. Cottrell, Colin Havenar-Daughton, Gabriel Ozorowski, Erik Georgeson, Oleksandr Kalyuzhniy, Jordan R. Willis, Michael Kubitz, Yumiko Adachi, Samantha M. Reiss, Mia Shin, Natalia de Val, Andrew B. Ward, Shane Crotty, Dennis R. Burton, William R. Schief   +20 more
doaj   +1 more source

Fusion of the molecular adjuvant C3d to cleavage-independent native-like HIV-1 Env trimers improves the elicited antibody response

Frontiers in Immunology, 2023
An effective HIV vaccine likely requires the elicitation of neutralizing antibodies (NAbs) against multiple HIV-1 clades. The recently developed cleavage-independent native flexibly linked (NFL) envelope (Env) trimers exhibit well-ordered conformation ...
Shridhar Bale, Lifei Yang, Mehrdad Alirezaei, Richard Wilson, Takayuki Ota, Esmeralda D. Doyle, Christopher A. Cottrell, Javier Guenaga, Karen Tran, Wenjuan Li, Leonidas Stamatatos, Leonidas Stamatatos, David Nemazee, Andrew B. Ward, Andrew B. Ward, Andrew B. Ward, Richard T. Wyatt, Richard T. Wyatt, Richard T. Wyatt   +18 more
doaj   +1 more source

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge [PDF]

, 2016
End-stage liver disease caused by hepatitis C virus (HCV) infection is a major indication for liver transplantation. However, immediately after transplantation the liver graft of viremic patients universally becomes infected by circulating virus ...
Baumert, Thomas F., Cole, Sarah, Desombere, Isabelle, Fafi-Kremer, Samira, Farhoudi, Ali, Heydmann, Laura, Leroux-Roels, Geert, McKeating, Jane A., Meuleman, Philip, Patel, Arvind H., Pessaux, Patrick, Van Houtte, Freya, Verhoye, Lieven   +12 more
core   +3 more sources

Intracellular Antibody Neutralizes Listeria Growth [PDF]

Immunity, 2001
We previously reported that treatment of mice with a neutralizing mAb against listeriolysin O (LLO), the pore-forming toxin of Listeria monocytogenes, provided resistance to this intracellular bacterium. We evaluated whether anti-LLO mAb would affect Listeria handling by macrophages, essential cells in Listeria resistance.
Edelson, Brian T, Unanue, Emil R
openaire   +2 more sources

Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers

Retrovirology, 2018
Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viruses, are a major focus of HIV vaccine design, with data from animal studies confirming their ability to prevent HIV infection.
Elise Landais, Penny L. Moore
doaj   +1 more source

Single-domain antibodies and their formatting to combat viral infections [PDF]

, 2018
Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies, De Vlieger, Dorien, Rossey, Iebe, Saelens, Xavier, Schepens, Bert   +4 more
core   +2 more sources

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group [PDF]

, 2010
The Global HIV Vaccine Enterprise convened a meeting of a Working Group in July 2009 to discuss recent progress in rational design of the components of an HIV vaccine, such as inserts, vectors and adjuvants,and in understanding antigen processing and ...
John Mascola, Ralph Steinman, Richter C. King, the Working Group convened by the Global HIV Vaccine Enterprise   +3 more
core   +3 more sources

In vivo Neutralization of Pro-inflammatory Cytokines During Secondary Streptococcus pneumoniae Infection Post Influenza A Virus Infection [PDF]

, 2019
An overt pro-inflammatory immune response is a key factor contributing to lethal pneumococcal infection in an influenza pre-infected host and represents a potential target for therapeutic intervention.
Boehme, Julia D., Bruder, Dunja, Christen, Henrike, Guzmán, Carlos A., Hernandez-Vargas, Esteban A., Kershaw, Olivia, Schreiber, Jens, Sharma-Chawla, Niharika, Stegemann-Koniszewski, Sabine   +8 more
core   +1 more source